Gemtuzumab Ozogamicin — Drug Intelligence | 12 EU Trials

Filter these 12 trials by condition, phase, country and more.

Open in Search →

12 Registered trials

8 Recruiting

3 Completed trials

9 Sponsors

21 Countries

Phase III

Phase II

Phase I/II

Phase III: 7 Phase II: 3 Phase I/II: 2

Oversight events:

1 serious breach 6 temporary halts 1 urgent safety measure across 2 trials

View oversight register →

Indications tested

Acute myeloid leukaemia 3

Sponsors using this IMP

Prinses Maxima Centrum voor Kinderoncologie B.V. 2 Technische Universitat Dresden 2 The University Of Birmingham 2 Associazione Italiana Ematologia Oncologia Pediatrica 1 Centre Antoine Lacassagne 1 Fondazione Gimema Franco Mandelli Onlus 1 GPOH gGmbH 1 Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l. 1 Medical University Of Lodz 1

All trials

12 total

IMPACT-AML: A RANDOMIZED PRAGMATIC CLINICAL TRIAL FOR RELAPSE OR REFRACTORY ACUTE MYELOID LEUKEMIA Recruiting

2024-514517-35-00 Phase III 7 countries Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.
VICTOR: Venetoclax or Intensive Chemotherapy for Treatment Of Favourable Risk Acute Myeloid Leukaemia: a molecularly guided phase 2 study Recruiting

2024-516116-19-00 Phase II 1 country The University Of Birmingham
MAGIC AML - Multiarm, Multicenter, RAndomized, Molecularly-GuIded Controlled Trial of Personalized Treatment Strategy - of Acute Myeloid Leu… Recruiting

2023-503394-37-00 Phase III 1 country Medical University Of Lodz
Venetoclax plus azacitidine versus standard intensive chemotherapy for patients with newly diagnosed acute myeloid leukemia (AML) and NPM1 m… Recruiting

2024-515267-59-00 Phase II 1 country Technische Universitaet Dresden
CHIP-AML22 Master protocol: Protocol for the treatment of children and adolescents with Acute Myeloid Leukemia (AML) Recruiting

2023-504999-25-00 Phase III 12 countries Prinses Maxima Centrum voor Kinderoncologie B.V.
Venetoclax in children with relapsed AML Recruiting

2023-510160-12-00 Phase III 14 countries Prinses Maxima Centrum voor Kinderoncologie B.V.
Study to determine the efficacy of Gemtuzumab Ozogamicin, together with standard chemotherapy, on minimal residual disease levels, in adult … Recruiting

2023-510433-29-00 Phase III 1 country Fondazione Gimema Franco Mandelli Onlus
Midostaurin + Gemtuzumab Ozogamicin combination in first-line standard therapy for acute myeloid leukemia (MOSAIC) Recruiting

2024-514014-13-00 Phase I/II 1 country Technische Universitaet Dresden
ICC APL STUDY 02 Treatment study for children and adolescents with Acute Promyelocytic Leukemia Ended

2024-518669-83-00 Phase II 5 countries Associazione Italiana Ematologia Oncologia Pediatrica
STUDY AGORA-1 / ALFA 2100: Phase 2 on the combinaison of Gemtuzumab Ozogamicin witk gilteritinib in adult patients with acute myeloid leukem… Ended

2023-504176-25-00 Phase I/II 1 country Centre Antoine Lacassagne
Myechild 01: International Randomised Phase III Clinical Trial in Children with Acute Myeloid Leukaemia - Incorporating an Embedded Dose Fin… Ended

2024-516112-21-00 Phase III 2 countries The University Of Birmingham
International multicenter, open-label clinical trial for the treatment of acute myeloid leukemia in children and adolescents Halted

2022-500783-35-00 Phase III 6 countries GPOH gGmbH

Showing 1–12 of 12 trials

← All drugs A–Z